Search Results - "Unger, Sigrun"

First evaluation of the safety, pharmacokinetics, and pharmacodynamics of BAY 2433334, a small molecule targeting coagulation factor XIa by Thomas, Dirk, Kanefendt, Friederike, Schwers, Stephan, Unger, Sigrun, Yassen, Ashraf, Boxnick, Stefanie

“…Background Coagulation factor XI (FXI) contributes to the development of thrombosis but appears to play a minor role in hemostasis and is, therefore, an…”
Get full text

Clinical Pharmacokinetic and Pharmacodynamic Profile of Riociguat by Frey, Reiner, Becker, Corina, Saleh, Soundos, Unger, Sigrun, van der Mey, Dorina, Mück, Wolfgang

“…Oral riociguat is a soluble guanylate cyclase (sGC) stimulator that targets the nitric oxide (NO)–sGC–cyclic guanosine monophosphate pathway with a dual mode…”
Get full text

Acute Hemodynamic Effects of Riociguat in Patients With Pulmonary Hypertension Associated With Diastolic Heart Failure (DILATE-1) by Bonderman, Diana, MD, Pretsch, Ingrid, MD, Steringer-Mascherbauer, Regina, MD, Jansa, Pavel, MD, Rosenkranz, Stephan, MD, Tufaro, Caroline, MS, Bojic, Andja, MD, Lam, Carolyn S. P, MD, Frey, Reiner, MD, Ochan Kilama, Michael, MD, Unger, Sigrun, MSc, Roessig, Lothar, MD, Lang, Irene M, MD

“…BACKGROUND Deficient nitric oxide-soluble guanylate cyclase-cyclic guanosine monophosphate signaling results from endothelial dysfunction and may underlie…”
Get full text

BAY 1213790, a fully human IgG1 antibody targeting coagulation factor XIa: First evaluation of safety, pharmacodynamics, and pharmacokinetics by Thomas, Dirk, Thelen, Kirstin, Kraff, Stefanie, Schwers, Stephan, Schiffer, Sonja, Unger, Sigrun, Yassen, Ashraf, Boxnick, Stefanie

“…Coagulation factor XI (FXI) contributes to the development of thrombosis but appears to play only a minor role in hemostasis and is therefore an attractive…”
Get full text

Single-Dose Pharmacokinetics, Pharmacodynamics, Tolerability, and Safety of the Soluble Guanylate Cyclase Stimulator BAY 63-2521: An Ascending-Dose Study in Healthy Male Volunteers by Frey, Reiner, Mück, Wolfgang, Unger, Sigrun, Artmeier-Brandt, Ulrike, Weimann, Gerrit, Wensing, Georg

“…The aim of the study was to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of BAY 63–2521, a new drug in development for pulmonary…”
Get full text

Assessment of the Effects of Hepatic Impairment and Smoking on the Pharmacokinetics of a Single Oral Dose of the Soluble Guanylate Cyclase Stimulator Riociguat (BAY 63-2521) by Frey, Reiner, Becker, Corina, Unger, Sigrun, Schmidt, Anja, Wensing, Georg, Mück, Wolfgang

“…Riociguat, a soluble guanylate cyclase stimulator developed for the treatment of pulmonary hypertension, is metabolized in part by the liver. Expression of one…”
Get full text

Pharmacokinetic interaction of riociguat and antiretroviral combination regimens in HIV-1-infected adults by DeJesus, Edwin, Saleh, Soundos, Cheng, Sue, van der Mey, Dorina, Becker, Corina, Frey, Reiner, Unger, Sigrun, Mueck, Wolfgang

“…Riociguat, a first-in-class soluble guanylate cyclase stimulator, is approved for the treatment of pulmonary arterial hypertension (PAH), a serious potential…”
Get full text

Assessment of the Effects of Renal Impairment and Smoking on the Pharmacokinetics of a Single Oral Dose of the Soluble Guanylate Cyclase Stimulator Riociguat (BAY 63-2521) by Frey, Reiner, Becker, Corina, Unger, Sigrun, Schmidt, Anja, Wensing, Georg, Mück, Wolfgang

“…Renal impairment is a common comborbidity in patients with pulmonary hypertension. The breakdown of riociguat, an oral soluble guanylate cyclase stimulator…”
Get full text

Absorption of Riociguat (BAY 63-2521): Bioavailability, Food Effects, and Dose Proportionality by Becker, Corina, Frey, Reiner, Hesse, Christiane, Unger, Sigrun, Reber1, Michael, Mück, Wolfgang

“…Riociguat (BAY 63-2521) is the first member of a novel class of compounds, the soluble guanylate cyclase (sGC) stimulators. Riociguat has a dual mode of…”
Get full text

Bioavailability, Pharmacokinetics, and Safety of Riociguat Given as an Oral Suspension or Crushed Tablet with and without Food by Saleh, Soundos, Frey, Reiner, Becker, Corina, Unger, Sigrun, Wensing, Georg, Mück, Wolfgang

“…Riociguat is approved for the treatment of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension. Some patients have difficulty…”
Get full text

Acute effects of riociguat in borderline or manifest pulmonary hypertension associated with chronic obstructive pulmonary disease by Ghofrani, Hossein A., Staehler, Gerd, Grünig, Ekkehard, Halank, Michael, Mitrovic, Veselin, Unger, Sigrun, Mueck, Wolfgang, Frey, Reiner, Grimminger, Friedrich, Schermuly, Ralph T., Behr, Juergen

“…Riociguat is the first oral soluble guanylate cyclase stimulator shown to improve pulmonary hemodynamics in patients with pulmonary arterial hypertension and…”
Get full text

Riociguat (BAY 63-2521) and Aspirin: A Randomized, Pharmacodynamic, and Pharmacokinetic Interaction Study by Frey, Reiner, Reber, Michael, Krätzschmar, Jörn, Unger, Sigrun, Mück, Wolfgang, Wensing, Georg

“…In preclinical studies, drugs that increase cyclic guanosine monophosphate levels have been shown to influence platelet function/aggregation; however, the…”
Get full text

Pharmacokinetic Interaction of Riociguat with Ketoconazole, Clarithromycin, and Midazolam by Becker, Corina, Frey, Reiner, Unger, Sigrun, Thomas, Dirk, Reber, Michael, Weimann, Gerrit, Dietrich, Hartmut, Arens, Erich R., Mück, Wolfgang

“…Riociguat is a soluble guanylate cyclase stimulator for the treatment of pulmonary hypertension that is principally metabolized via the cytochrome P450 (CYP)…”
Get full text

Pharmacokinetic Interaction Study between Riociguat and the Combined Oral Contraceptives Levonorgestrel and Ethinylestradiol in Healthy Postmenopausal Women by Frey, Reiner, Unger, Sigrun, van der Mey, Dorina, Becker, Corina, Saleh, Soundos, Wensing, Georg, Mück, Wolfgang

“…Female patients requiring treatment for pulmonary arterial hypertension (PAH) are advised to avoid pregnancy because of the high associated mortality rate…”
Get full text

Effects of Omeprazole and Aluminum Hydroxide/Magnesium Hydroxide on Riociguat Absorption by Becker, Corina, Frey1, Reiner, Unger, Sigrun, Artmeier-Brandt, Ulrike, Weimann, Gerrit, Mück, Wolfgang

“…Riociguat, a soluble guanylate cyclase stimulator, is a novel therapy for the treatment of pulmonary hypertension. Riociguat bioavailability is reduced in…”
Get full text

Acute hemodynamic effects of riociguat in patients with pulmonary hypertension associated with diastolic heart failure (DILATE-1): a randomized, double-blind, placebo-controlled, single-dose study by Bonderman, Diana, Pretsch, Ingrid, Steringer-Mascherbauer, Regina, Jansa, Pavel, Rosenkranz, Stephan, Tufaro, Caroline, Bojic, Andja, Lam, Carolyn S P, Frey, Reiner, Ochan Kilama, Michael, Unger, Sigrun, Roessig, Lothar, Lang, Irene M

“…Deficient nitric oxide-soluble guanylate cyclase-cyclic guanosine monophosphate signaling results from endothelial dysfunction and may underlie impaired…”
Get full text

Effects of Tablet Formulation, Food, or Gastric pH on the Bioavailability of Asundexian by Kanefendt, Friederike, Brase, Christine, Unger, Sigrun, Kubitza, Dagmar

“…ABSTRACT Absolute bioavailability (F) and the impact of gastric pH, tablet formulation, and food on the pharmacokinetics and safety of asundexian, an oral…”
Get full text

Cinaciguat (BAY 58―2667) Improves Cardiopulmonary Hemodynamics in Patients With Acute Decompensated Heart Failure by LAPP, Harald, MITROVIC, Veselin, FRANZ, Norbert, HEUER, Hubertus, BUERKE, Michael, WOLFERTZ, Judith, MUECK, Wolfgang, UNGER, Sigrun, WENSING, Georg, FREY, Reiner

“…Cinaciguat (BAY 58-2667) is the first of a new class of soluble guanylate cyclase activators in clinical development for acute decompensated heart failure. We…”
Get full text

BAY 2253651 for the treatment of obstructive sleep apnoea: a multicentre, double-blind, randomised controlled trial (SANDMAN) by Gaisl, Thomas, Turnbull, Chris D, Weimann, Gerrit, Unger, Sigrun, Finger, Rudolf, Xing, Charles, Cistulli, Peter A, West, Sophie, Chiang, Alan K I, Eckert, Danny J, Stradling, John R, Kohler, Malcolm

“…For obstructive sleep apnoea (OSA), few mechanical treatment options are available and no pharmacotherapy is approved [1–3]. However, safe and efficacious…”
Get full text

Pharmacokinetics, Safety, and Tolerability of the α2C‐Adrenoreceptor Antagonist BAY 1193397 in Healthy Male Subjects by Kapsa, Stefanie, Thuss, Uwe, Boxnick, Stefanie, Schaumann, Frank, Schultz, Armin, Unger, Sigrun, Otto, Christiane

“…The α2C‐adrenoreceptor antagonist BAY 1193397 is in development for the oral treatment of diabetic foot ulcers. Safety, tolerability, and pharmacokinetics of…”
Get full text